202 related articles for article (PubMed ID: 23266528)
1. Involvement of kinase PKC-zeta in the p62/p62(P392L)-driven activation of NF-κB in human osteoclasts.
Chamoux E; McManus S; Laberge G; Bisson M; Roux S
Biochim Biophys Acta; 2013 Mar; 1832(3):475-84. PubMed ID: 23266528
[TBL] [Abstract][Full Text] [Related]
2. The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts.
Chamoux E; Couture J; Bisson M; Morissette J; Brown JP; Roux S
Mol Endocrinol; 2009 Oct; 23(10):1668-80. PubMed ID: 19589897
[TBL] [Abstract][Full Text] [Related]
3. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.
Rea SL; Walsh JP; Ward L; Yip K; Ward BK; Kent GN; Steer JH; Xu J; Ratajczak T
J Bone Miner Res; 2006 Jul; 21(7):1136-45. PubMed ID: 16813535
[TBL] [Abstract][Full Text] [Related]
4. Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation, and a novel non-UBA domain mutation (P364S) associated with increased NF-kappaB signaling without loss of ubiquitin binding.
Rea SL; Walsh JP; Ward L; Magno AL; Ward BK; Shaw B; Layfield R; Kent GN; Xu J; Ratajczak T
J Bone Miner Res; 2009 Jul; 24(7):1216-23. PubMed ID: 19257822
[TBL] [Abstract][Full Text] [Related]
5. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation.
Sanz L; Sanchez P; Lallena MJ; Diaz-Meco MT; Moscat J
EMBO J; 1999 Jun; 18(11):3044-53. PubMed ID: 10356400
[TBL] [Abstract][Full Text] [Related]
6. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease.
Kurihara N; Hiruma Y; Zhou H; Subler MA; Dempster DW; Singer FR; Reddy SV; Gruber HE; Windle JJ; Roodman GD
J Clin Invest; 2007 Jan; 117(1):133-42. PubMed ID: 17187080
[TBL] [Abstract][Full Text] [Related]
7. p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone.
Yip KH; Feng H; Pavlos NJ; Zheng MH; Xu J
Am J Pathol; 2006 Aug; 169(2):503-14. PubMed ID: 16877352
[TBL] [Abstract][Full Text] [Related]
8. The LIM protein Ajuba influences interleukin-1-induced NF-kappaB activation by affecting the assembly and activity of the protein kinase Czeta/p62/TRAF6 signaling complex.
Feng Y; Longmore GD
Mol Cell Biol; 2005 May; 25(10):4010-22. PubMed ID: 15870274
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB
Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone.
Najat D; Garner T; Hagen T; Shaw B; Sheppard PW; Falchetti A; Marini F; Brandi ML; Long JE; Cavey JR; Searle MS; Layfield R
J Bone Miner Res; 2009 Apr; 24(4):632-42. PubMed ID: 19049332
[TBL] [Abstract][Full Text] [Related]
11. Hyperglycemia stimulates p62/PKCζ interaction, which mediates NF-κB activation, increased Nox4 expression, and inflammatory cytokine activation in vascular smooth muscle.
Xi G; Shen X; Wai C; Vilas CK; Clemmons DR
FASEB J; 2015 Dec; 29(12):4772-82. PubMed ID: 26231202
[TBL] [Abstract][Full Text] [Related]
12. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.
Hiruma Y; Kurihara N; Subler MA; Zhou H; Boykin CS; Zhang H; Ishizuka S; Dempster DW; Roodman GD; Windle JJ
Hum Mol Genet; 2008 Dec; 17(23):3708-19. PubMed ID: 18765443
[TBL] [Abstract][Full Text] [Related]
13. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
[TBL] [Abstract][Full Text] [Related]
14. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone.
Morissette J; Laurin N; Brown JP
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P38-44. PubMed ID: 17229007
[TBL] [Abstract][Full Text] [Related]
15. Paget's disease of bone in the French population: novel SQSTM1 mutations, functional analysis, and genotype-phenotype correlations.
Collet C; Michou L; Audran M; Chasseigneaux S; Hilliquin P; Bardin T; Lemaire I; Cornélis F; Launay JM; Orcel P; Laplanche JL
J Bone Miner Res; 2007 Feb; 22(2):310-7. PubMed ID: 17129171
[TBL] [Abstract][Full Text] [Related]
16. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
17. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.
Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J
J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045
[TBL] [Abstract][Full Text] [Related]
18. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease.
Kurihara N; Hiruma Y; Yamana K; Michou L; Rousseau C; Morissette J; Galson DL; Teramachi J; Zhou H; Dempster DW; Windle JJ; Brown JP; Roodman GD
Cell Metab; 2011 Jan; 13(1):23-34. PubMed ID: 21195346
[TBL] [Abstract][Full Text] [Related]
19. Three novel mutations in SQSTM1 identified in familial Paget's disease of bone.
Johnson-Pais TL; Wisdom JH; Weldon KS; Cody JD; Hansen MF; Singer FR; Leach RJ
J Bone Miner Res; 2003 Oct; 18(10):1748-53. PubMed ID: 14584883
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.
Ang E; Pavlos NJ; Rea SL; Qi M; Chai T; Walsh JP; Ratajczak T; Zheng MH; Xu J
J Cell Physiol; 2009 Aug; 220(2):450-9. PubMed ID: 19365810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
